Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
about
Novel immunotherapeutic strategies of gastric cancer treatmentDistinct effects of IL-18 on the engraftment and function of human effector CD8 T cells and regulatory T cellsIncreased immunogenicity of surviving tumor cells enables cooperation between liposomal doxorubicin and IL-18.Polyfunctional T-cell responses are disrupted by the ovarian cancer ascites environment and only partially restored by clinically relevant cytokines.IL-18 inhibits growth of murine orthotopic prostate carcinomas via both adaptive and innate immune mechanismsBlood cytokines as biomarkers of in vivo toxicity in preclinical safety assessment: considerations for their use.Targeting the NLRP3 inflammasome in chronic inflammatory diseases: current perspectives.Time-dependent cytotoxic drugs selectively cooperate with IL-18 for cancer chemo-immunotherapy.The emergence of immunomodulation: combinatorial immunochemotherapy opportunities for the next decade.Immunologic Function and Molecular Insight of Recombinant Interleukin-18Toxicity as a result of immunostimulation by biologics.The history of fever, leukocytic pyrogen and interleukin-1Targeting IL-17A attenuates neonatal sepsis mortality induced by IL-18.Effects of interleukin-18 on natural killer cells: costimulation of activation through Fc receptors for immunoglobulin.Folate-conjugated immunoglobulin targets melanoma tumor cells for NK cell effector functions.Immunomodulatory cytokines as therapeutic agents for melanomaA dose-escalation study of recombinant human interleukin-18 in combination with rituximab in patients with non-Hodgkin lymphomaInterleukin-18 and IL-18 binding protein.Association of IL-18 promoter polymorphism with liver disease severity in HCV-infected patients.Functions of γC cytokines in immune homeostasis: current and potential clinical applications.Multiparameter comparative analysis reveals differential impacts of various cytokines on CART cell phenotype and function ex vivo and in vivo.Oncolytic adenoviruses expressing interleukin: a novel antitumour approach.Cancer immunotherapy and nanomedicine.Utilizing cytokines to function-enable human NK cells for the immunotherapy of cancer.Targeting Immunotherapy to the Tumor Microenvironment.Immunomodulatory IL-18 binding protein is produced by prostate cancer cells and its levels in urine and serum correlate with tumor status.Oncolytic adenovirus expressing interleukin-18 induces significant antitumor effects against melanoma in mice through inhibition of angiogenesis.IL-12 immunotherapy of murine leukaemia: comparison of systemic versus gene modified cell therapy.Dendritic Cell Activity Driven by Recombinant Mycobacterium bovis BCG Producing Human IL-18, in Healthy BCG Vaccinated AdultsEmerging roles of endoglin/CD105 and angiogenic cytokines for disease development and progression in multiple myeloma patients.Interleukin (IL)-18, a biomarker of human ovarian carcinoma, is predominantly released as biologically inactive precursor.Enhanced suppression of pulmonary metastasis of malignant melanoma cells by combined administration of alpha-galactosylceramide and interleukin-18.Intra-tumoral production of IL18, but not IL12, by TCR-engineered T cells is non-toxic and counteracts immune evasion of solid tumors.Overview of the IL-1 family in innate inflammation and acquired immunity.Interleukin (IL)-18 Binding Protein Deficiency Disrupts Natural Killer Cell Maturation and Diminishes Circulating IL-18.Augmentation of Antitumor Immunity by Human and Mouse CAR T Cells Secreting IL-18.A Dose-escalation Study of Recombinant Human Interleukin-18 in Combination With Ofatumumab After Autologous Peripheral Blood Stem Cell Transplantation for Lymphoma.Mesenchymal Stem Cell Expressing TRAIL as Targeted Therapy against Sensitised TumourAnakinra Therapy for Non-cancer Inflammatory Diseases
P2860
Q27011232-86888BA8-F4FB-43F0-82BB-CA610984985EQ27438176-94CF7E77-CB6E-4B3C-A737-40FEF663443AQ33552702-1AAABD31-B94C-4C87-8CD7-0F8B0C9A5DB5Q33784707-AC51A34F-5E4E-468C-B642-131543B15F39Q34026026-FDC74DE1-B543-428B-883C-D79478F1BC7FQ34071983-47E4F4FB-A1F4-4F64-9709-12370E0B39FAQ35001511-0E8F0E73-A83B-47A3-918F-1FF1EC9E7F8BQ35053993-B1370F28-E606-4A3B-A1C8-67549911D126Q35058213-9996FD57-9A32-4218-9043-293A9F14C9D3Q36092506-5721555D-6780-45A8-B2CF-7A5F4FBAE31EQ36788414-2352B02D-5EB2-4831-989D-AB0BE72C05D2Q36832667-15C600AD-F34E-436D-BFFA-384A700966C6Q36905009-A1FC1FB9-6265-4E9D-98A2-329E1AF1B0F0Q37000481-10FB4915-578E-490C-A1CB-FCD3C4A0C8F3Q37053016-CC38ACD8-14CC-4CB4-BCAC-8DB2FF1A0B19Q37070203-19713C7F-7A06-40BD-93B7-4B267126AADAQ37164093-F7D87FA4-9F1C-44BB-8402-B5B841966A60Q37220336-9271F576-EE15-4E68-97D7-EA5A84B70DD7Q37277880-603156C2-B5E7-4172-AD3B-8D0570EBF8A3Q37475949-DC1E3CC1-1FBF-41B4-952E-EE3E39D6A008Q37696129-D8A83E5E-166A-4BED-96E9-4E3C43DD44D1Q37733550-AD6686CF-8FBE-4881-A6F0-D1EB8C38C878Q37785836-56624BCD-E5C0-4D02-BF78-940F427636A8Q38233046-1021E228-020B-4AF5-9A41-C8D8C3213BCEQ39195213-313E0DBF-40CC-46F8-9C62-E5F3DAF75D1EQ39650148-7678A847-38F3-46FA-8DA4-BC6412CDE221Q39842445-7797E6F9-FC83-473D-9996-0CE0244A7BB3Q39961838-4D0269CD-68BF-4106-A6C8-2FF38BDDBF57Q41015596-C8BC5B9E-0976-4D6E-ABA2-EE560BC70112Q43864995-C218A1EC-6169-4C1F-BC92-D166DEEB13EFQ45807012-1F67F113-3563-4A59-8339-DC71E26DB8F7Q46940975-CED78770-3904-44B7-A41C-873CD17F26A9Q47163146-348884A3-926F-43E8-984C-88DE7EB69B56Q47285878-3C7041A4-95F9-4A09-AFA1-542B7225A323Q47813664-E1861A43-4337-4EF9-9D27-D2D78BEA4111Q48648729-FF0B0A39-F632-49DB-BDE2-E63E7441798DQ51742964-FB4A5C86-94A3-43C2-B426-7E1E1975BD90Q57174410-6EA0257B-2901-49FD-B4B2-4ED31AA07D40Q59136398-FD1AE577-6A70-4DA5-8D78-80F0F10901E6
P2860
Clinical and biological effects of recombinant human interleukin-18 administered by intravenous infusion to patients with advanced cancer.
description
2006 nî lūn-bûn
@nan
2006 թուականի Յուլիսին հրատարակուած գիտական յօդուած
@hyw
2006 թվականի հուլիսին հրատարակված գիտական հոդված
@hy
2006年の論文
@ja
2006年論文
@yue
2006年論文
@zh-hant
2006年論文
@zh-hk
2006年論文
@zh-mo
2006年論文
@zh-tw
2006年论文
@wuu
name
Clinical and biological effect ...... patients with advanced cancer.
@ast
Clinical and biological effect ...... patients with advanced cancer.
@en
type
label
Clinical and biological effect ...... patients with advanced cancer.
@ast
Clinical and biological effect ...... patients with advanced cancer.
@en
prefLabel
Clinical and biological effect ...... patients with advanced cancer.
@ast
Clinical and biological effect ...... patients with advanced cancer.
@en
P2093
P1476
Clinical and biological effect ...... patients with advanced cancer.
@en
P2093
Coreen Oei
Henry Koon
James W Mier
Jill Weisenbach
Kevin M Koch
Linda M Thurmond
Lini N Pandite
Lyndon C Kirby
Michael Atkins
Michael J Robertson
P304
P356
10.1158/1078-0432.CCR-06-0121
P407
P433
P577
2006-07-01T00:00:00Z